Thomas Morrow, MD

NuView Life Sciences fuses molecular biology with imaging technology using the radioactive nuclide Copper 64

Thomas Morrow, MD

A recent television mystery show I was watching had many people searching for a suspect without success — that is, until the authorities brought in a bloodhound to “sniff” out the suspect. The dog took them on an entirely new path and, of course, they found the suspect!

This story is a metaphor for our search for cancer. We send out a lot of people to search for a tumor: radiologists, nuclear medicine specialists, cytologists, gastroenterologists, pathologists, ultrasonographers, and other physicians and health care professionals — and they search blindly, hoping to find a tumor early enough to make a difference.

Even after the diagnosis, this Keystone Kops’ activity continues periodically or with each new symptom. And the physician and patient are never really sure if they are missing something too small to detect with existing technology. Is there still tumor out there metastatic to some distant place, slowly growing?

On the treatment front, pharmaceutical companies have developed targeted therapies that, to use another metaphor, hone-in on a receptor like a heat-seeking missile. But similar technology has yet to be created to actually help find the tumor.

Interesting development

To be fair, there have been new radiopharmaceuticals developed that are more sensitive to specific diseases, but if we could muse a bit, would it not be an interesting development to use a target technology approach as a radiological tool that would cause the resulting image to glow in the dark?

New imaging technology

Well, this idea is not mine and it has gone well beyond the muse stage. It is the idea of small, privately held company, NuView Life Sciences, located in Park City, Utah. Working in conjunction with several university medical centers across the country, they are on the cusp of an exciting new technology for imaging.

Their concept is to couple the rapidly expanding knowledge of molecular biology with the developments in imaging technology. They are doing this by taking a biomarker that is fused with a radioactive nuclide of copper (Copper 64). As Copper 64 decays, it emits a positron that can be detected by a positron emission tomography (PET) scanner.

To understand this technology, here is how a PET scanner works. Currently, about 90 percent of all PET scans use radioactive glucose as the imaging compound. The glucose is made to be radioactive by adding an atom of radioactive fluorine, which upon decaying emits the positron. The new molecule is called 2-fluorodeoxy-D-glucose (FDG). Once infused into the patient, FDG acts almost like regular glucose and is taken up by cells that are rapidly metabolizing glucose.

But, the cells cannot fully metabolize FDG and as a result, radioactive fluorine accumulates in the cells. So, in principle, those cells that are most actively metabolizing glucose “light up” as the radioactive decay occurs and the positron is emitted. Of note is that as this molecule decays it shoots out specific particles at around 180 degrees from each other. This action allows the camera to “plot” where the emission is occurring and can be processed into a three-dimensional image.

Overlay of images

But this is only half of the picture. The PET scan results are increasingly being co-registered with either a CT or MRI scan, allowing an overlay of the different images.The combination incorporates structure (CT and MRI) with function (PET) capabilities producing amazing potential for seeing exactly where the metabolically-active tumor is located.

But this new technology is not relying on glucose as the primary substrate as glucose is not as specific to tumors as we would like it to be.

Other biomarkers

NuView has chosen other biomarkers to seek out specific receptors that are in some way related to a specific type of tumor cell. For instance, for melanoma NuView has developed a radioactive tagged alpha-melanocyte-stimulating-hormone (MSH). This peptide binds specifically to melanocortin-1 receptors that are over-expressed on malignant melanoma cells. As this tagged alpha MSH binds to the receptor, it “lights up” the tumor cells like no other previous technology!

For prostate cancer, NuView has chosen to tag a compound called VPAC1. This is a receptor that is over expressed on prostate cancer cells and can be targeted with a special gene that is guided by a radioactive probe.

It is thought that this radiopharmaceutical imaging molecule will detect prostate cancer earlier than a urologist‘s finger or an elevated prostate specific antigen (PSA) level.

NuView is also working on a molecular imaging agent that targets sites of inflammation, infection, and non-Hodgkin’s lymphoma using a small molecule that is specific to white cells.

Studied in animals

None of these products are available yet. In fact, many have only been studied in animal models. The company has limited experience in patients. But the proof of concept has been done and it is only a matter of time until the investigational new drug applications are filed.

The biggest problem with the new technology is the difficulty and expense of creating the radioactive particles. This requires a cyclotron. Few institutions have access to this technology and because of the very short half life of the actual radioactive particle, the facility must be relatively close to the hospital that is conducting the PET scan.

In addition, many of these particles degrade over just a few hours. Thus, they cannot be shipped across the country.

Managed care implications

Medical imaging is one of the fastest growing sectors of the health care budget. It is creating huge challenges for insurers and payers attempting to control costs, and for good reasons. Let’s face it, humans are visual creatures. We love seeing things, like photographs, Facebook, weather maps, and tumor sites! And seeing leads to understanding and treating. Physicians have been searching for better imaging since Wilhelm Röntgen took the first X-ray of his wife’s hand on Dec. 22, 1895.

The number of imaging modalities has skyrocketed in the past quarter century. Despite the promise, the development of these new imaging radiopharmaceuticals will only make the management more challenging. But, they will give hope to millions of people facing an uncertain future. These imaging compounds are a picture of Tomorrow’s Medicine!

Thomas Morrow, MD, is the immediate past president of the National Association of Managed Care Physicians. He has 24 years of managed care experience at the payer or health plan level. Contact him at TMorrow@ManagedCareMag.com
The author is a director in the value-based health department at Genentech. He has had no other industry affiliations in the past three years. The views expressed in Tomorrow’s Medicine are the author’s alone.

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.